Australia's Peplin has raised $24 million to fund late-stage trials of a skin cancer gel. At the same time, Peplin announced that CEO Michael Alridge was exiting. Chairman Tom Wiggan will take over the CEO's title as well. GBS Venture Partners, MPM Capital and New Enterprise Associates contributed to the funds. Report